Recent cancer immunotherapies targeting immune checkpoint inhibitors (ICIs) such as anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) antibodies have led to durable remission across a wide variety of different cancer types. This evidence concerns the gene CD274 and cancer.